CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
动量输入(同类管理人):
持有人广度 +7.1% ·
股份流向 +9.1% ·
净新建仓位 +6.7%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q4 2024
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (被动) | 2.18M | — | $402.66M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (被动) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (被动) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Norges Bank ✦ (被动) | 535.68K | +1.8% | $98.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 372.22K | +1952.2% | $68.71M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 272.98K | -0.2% | $50.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 232.32K | +25.8% | $42.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 123.69K | +59.9% | $22.83M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 84.66K | 新增 | $15.63M | 0.0% | New | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 78.86K | +309.6% | $14.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 25 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 27 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| D. E. Shaw & Co. | $15.63M | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 555 持有人, 56.84M 股份, $9.32B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 2.04K 股 · $599,711
Director · 573 股 · $163,443
Officer · 3.71K 股 · $1.04M
Officer, Director · 6.50K 股 · $1.82M
Director · 28.73K 股 · $7.90M
Officer · 404 股 · $104,446
Officer · 1.21K 股 · $311,529
Officer · 736 股 · $190,278
Officer · 4.18K 股 · $1.08M
Officer · 1.27K 股 · $330,055
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论